Biopharmx Corp (BPMX) Short Interest Update
Biopharmx Corp (NYSE:BPMX) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 5,411,971 shares, a drop of 1.3% from the May 31st total of 5,482,142 shares. Based on an average trading volume of 1,426,269 shares, the days-to-cover ratio is currently 3.8 days. Approximately 10.4% of the shares of the stock are short sold.
Separately, ValuEngine upgraded shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 24th.
Biopharmx Corp (BPMX) opened at 0.4438 on Tuesday. The company’s 50 day moving average is $0.54 and its 200-day moving average is $0.51. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $1.22. The firm’s market cap is $32.90 million.
WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/27/biopharmx-corp-bpmx-short-interest-update.html.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.